Thermo Fisher Scientific
TMB-High Status Does Not Predict Opdivo-Yervoy Response in Pan-Tumor Analysis
In a retrospective analysis, tumor mutational burden was not associated with improved responses to combination immunotherapy, researchers found.
Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project
The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients.
Diagnostics Firms, Lab Providers Form Genomic Profiling Coalition
The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.
FDA Approves Thermo Fisher Scientific CDx for Genentech's Gavreto in NSCLC Patients With RET Fusions
Thermo Fisher said the assay is the first and, so far, only FDA-approved test of its kind for a targeted treatment for RET fusion-positive NSCLC.
Thermo Fisher Scientific, Hengrui Therapeutics Ink CDx Deal for Pyrotinib in HER2-Mutated NSCLC
Under the terms of the agreement Thermo Fisher will retain the rights to commercialize the companion test globally and seek regulatory approval.
Jul 11, 2019
Jun 20, 2018